OIPE IAP78 DEC 23 2005 PATENT & TRADEMARK OFFICE

IAP3 Rec'd PCT/PTO 23 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/501,692	**Customer No. 035811**
Filed	: July 15, 2004	
PCT No.	: PCT/US02/27936	
PCT Filed	: August 29, 2002	
Inventors	: Richard Smith-Carliss	Docket: END041182PCTUS
	: Frank S. Caruso	
	: Peter Crooks	
	: Kenneth J. Kellar	
	: Yingxian Xiao	
Title	: ANALGESICS AND METHODS	
	: OF USE	Dated: December 21, 2005

Mail Stop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard
$1472.00 Check
Petition In Response To Notice of Incomplete Nonprovisional Application
Copy of Postcard dated July 15, 2004
Copy of Specifications, claims, abstract, drawings and filing fee
Copy of postcard dated February 18, 2005
Copy of Transmittal Letter
Copy of Express Mail Certificate,
Copy of Combined Declaration, Power of Attorney and Petition (4 pages)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

DLA Piper Rudnick Gray Cary US LLP
Customer No. 35811

By: _____

Date: 21 DEC 2005

OIPE IAP78
DEC 23 2005
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/501,692	**Customer No. 035811**
Filed	: July 15, 2004	
Inventors	: Richard Smith-Carliss	Docket: END-04-1182PCT-US
	: Frank S. Caruso	
	: Peter Crooks	Confirmation No.: 4419
	: Kenneth J. Kellar	
	: Yingxian Xiao	
Title	: ANALGESICS AND METHODS	
	: OF USE	
		Dated: December 21, 2005

PETITION IN RESPONSE TO NOTICE OF INCOMPLETE NONPROVISIONAL APPLICATION

Mail Stop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Applicants are in receipt of a Notice of Incomplete Nonprovisional Application dated October 21, 2005, copy enclosed. It is indicated in that Notice that the specification is missing, the specification does not include at least one claim, the basic filing fee is missing, and that a new Declaration is now required.

The Applicants respectfully submit that the Applicants are entitled to a filing date of July 15, 2004, since the specification (26 pages), claims (13 pages), abstract and drawings (14 sheets) were filed on July 15, 2004.


A copy of the return postcard acknowledging receipt of the specification, claims, abstract, drawings and the filing fee is enclosed as well as a convenience copy of the specification, claims, abstract and drawings. The filing fee of $1072.00 included with the application as filed was credited to Deposit Account No. 50-2719 on March 4, 2005 for reasons unknown to the Applicants.

The Declaration was submitted on February 18, 2005, along with the $130.00 surcharge. A copy of the Declaration is enclosed along with a copy of the return postcard acknowledging receipt

on February 18, 2005.

The Applicants enclose a check in the amount of $1472.00 which covers both the application filing fee and the petition fee. Once the application is officially accorded its proper filing date of July 15, 2004, the Applicants respectfully request a refund of the $400.00 petition fee since the required documents were timely filed.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC:cc
(215)656-3381

OIPE IAP78 DEC 23 2005 PATENT & TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/501,692	07/15/2004	Richard Smith-Carliss	END041182PCTUS

CONFIRMATION NO. 4419

FORMALITIES LETTER

035811
IP GROUP OF DLA PIPER RUDNICK GRAY CARY US LLP
1650 MARKET ST
SUITE 4900
PHILADELPHIA, PA 19103

RECEIVED
OCT 26 2005
PCT

RESPONSE DUE 12/21/05 CCLT RB

Date Mailed: 10/21/2005

NOTICE OF INCOMPLETE NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

A filing date has NOT been accorded to the above-identified application papers for the reason(s) indicated below.

All of the items noted below **and a newly executed oath or declaration covering the items must** be submitted within **TWO MONTHS** of the date of this Notice, unless otherwise indicated, or proceedings on the application will be terminated *(37 CFR 1.53(e))*. Replies should be mailed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

The filing date will be the date of receipt of all items required below, unless otherwise indicated. Any assertions that the item(s) required below were submitted, or are not necessary for a filing date, must be by way of petition directed to the attention of the Office of Petitions accompanied by the $400.00 petition fee *(37 CFR 1.17(f))*. If the petition states that the application is entitled to a filing date, a request for a refund of the petition fee may be included in the petition. Petitions should be mailed to: Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- The specification is missing.
- The specification does not include at least one claim.
 A complete specification as prescribed by 35 U.S.C. 112 is required.

- The statutory basic filing fee is missing.
 Applicant must submit $ **300** *to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).*

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

SUMMARY OF FEES DUE:

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/501,692	07/15/2004	Richard Smith-Carliss	END041182PCTUS

CONFIRMATION NO. 4419

035811
IP GROUP OF DLA PIPER RUDNICK GRAY CARY US LLP
1650 MARKET ST
SUITE 4900
PHILADELPHIA, PA 19103

FORMALITIES LETTER

Date Mailed: 10/21/2005

NOTICE OF INCOMPLETE NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

A filing date has NOT been accorded to the above-identified application papers for the reason(s) indicated below.

All of the items noted below **and a newly executed oath or declaration covering the items must** be submitted within **TWO MONTHS** of the date of this Notice, unless otherwise indicated, or proceedings on the application will be terminated *(37 CFR 1.53(e))*. Replies should be mailed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

The filing date will be the date of receipt of all items required below, unless otherwise indicated. Any assertions that the item(s) required below were submitted, or are not necessary for a filing date, must be by way of petition directed to the attention of the Office of Petitions accompanied by the $400.00 petition fee *(37 CFR 1.17(f))*. If the petition states that the application is entitled to a filing date, a request for a refund of the petition fee may be included in the petition. Petitions should be mailed to: Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- The specification is missing.
- The specification does not include at least one claim.
 A complete specification as prescribed by 35 U.S.C. 112 is required.

- The statutory basic filing fee is missing.
 Applicant must submit $ **300** *to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).*

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is **$870** for a Large Entity

- **$300** Statutory basic filing fee.

- The application search fee has not been paid. Applicant must submit **$500** to complete the search fee.
- The application examination fee has not been paid. Applicant must submit **$200** to complete the examination fee for a large entity

(A previous payment of **$130** will be applied to the additional fees indicated above.)

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

P. Phuong

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 3 - OFFICE COPY

Total additional fee(s) required for this application is **$870** for a Large Entity

- **$300** Statutory basic filing fee.

- The application search fee has not been paid. Applicant must submit **$500** to complete the search fee.
- The application examination fee has not been paid. Applicant must submit **$200** to complete the examination fee for a large entity

(A previous payment of **$130** will be applied to the additional fees indicated above.)

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

P. Phuong

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 2 - COPY TO BE RETURNED WITH RESPONSE

OIPE IAP78
DEC 28 2005
PATENT & TRADEMARK OFFICE

New U.S. Continuation Application based on PCT/US02/27936 filed 8/29/02 for Richard Smith-Carliss et al. entitled ANALGESICS AND METHODS OF USE
Express Mail Label EV548522605US

DT03 Rec'd PCT/PTO 15 JUL 2004

Dated: July 15, 2004

Docket No.: END-04-1182PCT-US

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OIPE
JUL 15 2004
PATENT & TRADEMARK OFFICE
JC22

Sir: Kindly date stamp this card and return it to the undersigned to evidence receipt of the enclosed $7,330.00 Check, $1,072.00 Check, Express Mail Certificate, Petition to Revive Under 37 C.F.R. §1.137(b), in duplicate, Application Transmittal Letter, in duplicate, Application Data Sheet (2 pages), Specification (26 pages), claims (13 pages), Abstract (1 page) and drawings (14 pages). Thank you.

TDC:rb

RECEIVED
JUL 2004
IP DEPT

ANALGESICS AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of priority to US provisional application serial no. 60/315,530 filed on August 29, 2001, which is hereby incorporated by reference in its entirety.

FIELD OF INVENTION

The invention relates to d-methadone metabolites and their analogs, as well as to methods of their use to induce analgesia and/or to inhibit abuse of abusive substances such as opioids, cocaine, nicotine, etc.

DESCRIPTION OF THE RELATED ART

The study of pain and pain alleviation has made it clear that the development of pain alleviation is not a singular path. Many, varied sources of pain and its alleviation are known and suspected. For this reason, scientists continually search for more, different, and better ways of treating pain and of reducing side effects associated therewith.

Nicotinic acetylcholine receptors are distributed throughout the central and peripheral nervous systems where they mediate the actions of endogenous acetylcholine, as well as nicotine and other nicotinic agonists. They are often associated with cell bodies and axons of major neurotransmitter systems, and nicotinic agonists are thought to act through these receptors to promote the release of a number of neurotransmitters such as dopamine, norepinephrine, γ-aminobutyric acid, acetylcholine, and glutarnate (for review, see Wonnacott, 1997), as well as certain pituitary hormones (Andersson et al., 1983; Sharp et al., 1987; Flores et al., 1989; Hulihian-Giblin et al., 1990). The release of this wide array of neurotransmitters and hormones probably contributes to the diverse, and sometimes opposite, effects of nicotine. For example, the release of norepinephrine is usually associated with arousal, while the stimulation of γ-aminobutyric acid systems is associated with sedation.

Nicotine was first examined for its potential as an analgesic drug almost 70 years ago (Davis et al., 1932), but its dose-response relationship for analgesia yielded a poor therapeutic index, which did not favor its development. More recently, following the discovery of the analgesic properties of epibatidine, a potent nicotinic agonist isolated from the skin of an Ecuadorian frog by Daly and colleagues (Spande et al., 1992), there has been renewed interest in the analgesic potential of drugs that act at nicotinic receptors (Bannon et al., 1998; Flores and Hargreaves, 1998; Flores, 2000).

It is likely that more than one neurotransmitter system plays an important role in analgesia. For example, methadone, a synthetic μ-opioid agonist, has analgesic properties similar to those of morphine (Kristensen et al., 1995), and it is also useful in the treatment of opiate addiction. Most of the morphine-like analgesic properties of (±)-methadone are as ascribed to the (-)-enantiomer, since the (+)-enantiomer has much weaker opiate properties (Scott et al., 1948; Smits and Myers. 1974; Homg et al., 1976). However, (+)-methadone does show analgesic potency in some experimental models (Shimoyama et al., 1997; Davis and Inturrisi, 1999), and it also appears to attenuate development of morphine tolerance (Davis and Inturrisi, 1999).

In addition to its agonist action at opiate receptors, methadone competes for [^{3}H]MK801 binding sites within the NMDA receptor channel and blocks NMDA receptor-mediated responses (Ebert et al., 1995); furthermore, the two enantiomers of methadone are nearly equipotent at [^{3}H]MK801 binding sites (Gorman et al., 1997). Several drugs such as MK801, phencyclidine, dextromethorphan, and dextrorphan, that block NMDA receptors, also block neuronal nicotinic receptors (Ramoa et al., 1990; Amador and Dani, 1991; Hernandez et al., 2000). Both nicotinic receptors and NMDA receptors have been implicated in pain pathways and possible mechanisms underlying the perception of pain. Therefore, the inventors examined the effects of methadone, its metabolites, and structural analogs (Fig. 1) on neuronal nicotinic receptors.

In addition to being involved in pain alleviation, recently, it has been discovered that certain nicotinic receptors may play a role in limiting abusive behavior.

Substances which may be subject to abuse include opioids, methamphetamines, hallucinogens, psychotropics, cocaine, and others. Some abusive substances are subtle and pervasive. Perhaps one of the most pervasive is nicotine, found in tobacco products. The term "abusive substances," as used herein, refers to any substance that can lead to abuse by creating dependence or otherwise inducing drug-seeking behavior.

During their research into d-methadone and its metabolites, EMDP and EDDP, the inventors discovered that the EMDP and EDDP and novel analogs thereof induce analgesia and may be useful in independently or simultaneously deterring abuse of one or more abusive substances listed above.

SUMMARY OF THE INVENTION

A method for inducing analgesia and/or inhibiting abuse of abusive substances includes administration of EMDP, EDDP, and novel analogs thereof. The compounds of the present invention may be incorporated into a suitable pharmaceutical composition for administration to

patients. The invention includes novel compounds, a method for inducing analgesia and/or inhibiting abuse of an abusive substance, and pharmaceutical compositions for use in the method.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the chemical structures of methadone, EMDP, EDDP, analogs, and mecamylamine.

Fig. 2 is a graph depicting the effects of methadone versus nicotine on $^{86}Rb^{+}$ efflux from KXα3β4R2 cells.

Fig. 3 is a graph depicting the inhibition of nicotine-stimulated $^{86}Rb^{+}$efflux: from KXα3β4R2 cells by methadone and its two enantiomers.

Fig. 4 is a graph depicting the competition by methadone for [^{3}H]EB binding sites in membrane homogenates from KXα3β4R2 cells.

Fig. 5 is a graph depicting the noncompetitive inhibition of nicotine-stimulated $^{86}Rb^{+}$ efflux from KXα3β4R2 cells by methadone.

Fig. 6 is a graph depicting the comparison of the inhibition of nicotine-stimulated $^{86}Rb^{+}$ efflux from KXα3β4R2 cells by methadone, (+)-EDDP, LAAM, and mecamylamine.

Fig. 7 is a graph depicting the noncompetitive inhibition of nicotine-stimulated $^{86}Rb^{+}$ efflux from KXα3β4R2 cells by (+)-EDDP and LAAM.

Fig. 8 is a schematic of a synthesis reaction scheme for making various compounds in accordance with the invention.

Fig. 9 is another schematic of a synthesis reaction scheme for making various compounds in accordance with the invention.

Fig. 10 is a graph showing the analgesic effect of EDDP.

Fig. 11 depicts sample current inhibition by EDDP.

Fig. 12 depicts a concentration response curve.

Fig. 13 is a graph comparing the Glutamate stimulated Catecholamine release with treatment with MK-801, d-methadone, and R(+)EDDP in the hippocampus.

Fig. 14 is a graph comparing the Glutamate stimulated Catecholamine release with treatment with MK-801, d-methadone, and R(+)EDDP in the striatum.

DETAILED DESCRIPTION

DEFINITIONS

Throughout this specification, reference simply to "the metabolites" or "d-methadone metabolites," means EDDP and EMDP, as defined below, and the pharmaceutically acceptable salts thereof, unless otherwise indicated.

The term "(+)-methadone" means S-(+)-methadone hydrochloride;

the term "(-)-methadone" means R-(-)-methadone hydrochloride;

the term "LAAM" means (-)-α-acetylmethadol hydrochloride;

the term "(+)-EDDP" means R-(+)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate;

the term "(-)-EDDP" means S-(-)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate;

the term "(+)-EMDP" means R-(+)-2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline hydrochloride;

the term (-)-EMDP" means S-(-)-2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline hydrochloride;

the term "EMDP" means (+)-EMDP, (-)-EMDP, or mixtures thereof;

the term "EDDP" means (+)-EDDP, (-)-EDDP, or mixtures thereof.

Despite the structural similarity to d-methadone, EMDP and EDDP, and analogs thereof, have different properties from d-methadone. Figs. 13 and 14 demonstrate this by comparing the effect of MK-801, d-methadone and (+)-EDDP on glutamate stimulated catecholamine release in rat brain slices from the hippocampus and striatum. The hippocampus and striatum are both important and well-studied anatomical areas of the brain. The hippocampus is associated with learning and memory functions while the striatus is linked to motor function. Slices were loaded with [^{3}H]norepinephrine or [^{3}H]dopamine and then exposed to 1 mM glutamate for 2 min in the absence or presence of MK-801, d-methadone or (+)-EDDP. The baseline release was measured in the absence of glutamate. These results indicate, that (+)-EDDP is physiologically different from d-methadone, an opioid blocker, and MK-801, an NMDA blocker. This difference is apparent from the dose shift to the right, as seen in both Figs. 13 and 14. Just 10μM of d-methadone or MK-801 achieves partial block of catecholamine release while no effect is seen from (+)-EDDP until 100μM.

The inventors believe, without being limited to this theory, that the success of the compounds of the present invention in inducing analgesia and/or inhibiting abuse is in their

ability to block the nicotinic receptors. It should be noted, however, that binding or blocking of other sites may also contribute to the effect.

The action of d-methadone and the compounds of the present invention at α3β4 neuronal nicotinic receptors stably expressed in human embryonic kidney 293 cells was measured. These compounds are potent nicotinic receptor blockers. One of the compounds disclosed herein is among the most potent nicotinic receptor blockers that have been reported.

Effects of Methadone and Related Drugs on nAChRs

Experimental Procedures

Materials and Drugs. Tissue culture medium, antibiotics, and serum were obtained from Invitrogen (Carlsbad, CA). [^{3}H](±)-epibatidine and [^{86}Rb]rubidium chloride ($^{86}Rb^+$) were obtained from PerkinElmer Life Science Products (Boston, MA). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. (±)-Methadone hydrochloride (methadone), *S*-(+)-methadone hydrochloride [(+)-methadone], and R-(-)-methadone hydrochloride [(-)-methadone] were obtained from Sigma/RBI (Natick, MA). The following compounds were obtained from Research Triangle Institute (Research Triangle Park, NC) through the National Institute on Drug Abuse: (-)-α-acetylmethadol hydrochloride (LAAM, a methadone analog); *R*-(+)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate [(+)-EDDP, a methadone metabolite]; *S*-(-)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate [(-)-EDDP, a methadone metabolite]; R-(+)-2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline hydrochloride [(+)-EMDP, a methadone metabolite]; *S*-(-)-2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline hydrochloride [(-)-EMDP, a methadone metabolite]; (+)-α-propoxyphene hydrochloride (a methadone analog); and (+)-α-*N*-norpropoxyphene maleate (a propoxyphene metabolite). The structures of methadone, EMDP, EDDP, and several analogs used here are shown in Fig. 1, along with mecamylamine, a well-known nicotinic channel blocker.

Cell Culture. The cell line KXα3β4R2 was established previously by stably cotransfecting human embryonic kidney 293 cells with the rat α3 and β4 nAChR subunits genes (Xiao et al., 1998). Cells were maintained in minimum essential medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, and 0.7 mg/ml of geneticin (G418) at 37°C with 5% CO_2 in a humidified incubator.

$^{86}Rb^+$ Efflux Assay. Function of nAChRs expressed in the transfected cells was measured using a $^{86}Rb^+$ efflux assay as described previously (Xiao et al., 1998). In brief, cells in the selection growth medium were plated into 24-well plates coated with poly(D-lysine). The plated cells were grown at 37°C for 18 to 24 h to reach 70 to 95% confluence. The cells were then incubated in growth medium (0.5 ml/well) containing $^{86}Rb^+$ (2 μCi/ml) for 4 h at 37°C. The

loading mixture was then aspirated and the cells were washed three times with buffer (15 mM HEPES, 140 mM NaCl, 2 mM KCl, 1 mM $MgSO_4$, 1.8 mM CaCl, 11 mM glucose, pH 7.4; 1 ml/well) for 30 s, 5 min, and 30 s, respectively. One milliliter of buffer, with or without compounds to be tested, was then added to each well. After incubation for 2 min, the assay buffer was collected for measurements of $^{86}Rb^+$ released from the cells. Cells were then lysed by adding 1 ml of 100 mM NaOH to each well, and the lysate was collected for determination of the amount of $^{86}Rb^+$ that was in the cells at the end of the efflux assay. Radioactivity of assay samples and lysates was measured by liquid scintillation counting. Total loading (cpm) was calculated as the sum of the assay sample and the lysate of each well. The amount of $^{86}Rb^+$ efflux was expressed as a percentage of $^{86}Rb^+$ loaded. Stimulated $^{86}Rb^+$ efflux was defined as the difference between efflux in the presence and absence of nicotine.

Experiments with antagonists were done in two different ways. For obtaining an IC_{50} value, inhibition curves were constructed in which different concentrations of an antagonist were included in the assay to inhibit efflux stimulated by 100 mM nicotine. For determination of the mechanism of antagonist blockade, concentration-response curves for receptor activation by nicotine were constructed in the presence or absence of an antagonist. The maximal nicotine stimulated $^{86}Rb^+$ efflux (E_{max}) was defined as the difference between maximal efflux in the presence of nicotine and basal efflux. EC_{50}, E_{max}, and IC_{50}, values were determined by nonlinear least-squares regression analyses (GraphPad, San Diego, CA).

Ligand Binding Studies. The ability of compounds to compete for the agonist recognition site of nAChRs was determined in ligand binding studies as described previously (Houghtling et at., 1995; Xiao et al.,1998). Briefly, membrane preparations were incubated with [^{3}H]EB for 4 h at 24°C. Bound and free ligands were separated by vacuum filtration through Whatman GF/C filters treated with 0.5% polyethylenimine. The radioactivity retained on the filters was measured by liquid scintillation counting. Total binding and nonspecific binding were determined in the absence and presence of (-)-nicotine (300 μM) respectively. Specific binding was defined as the difference between total binding and nonspecific binding. Binding curves were generated by incubating a series of concentrations of each compound with a single concentration of [^{3}H]EB. The IC_{50} and K_i values of binding inhibition curves were determined by nonlinear least squares regression analyses.

Results

Effects of Methadone on $^{86}Rb^+$ Efflux from KXα3β4R2 Cells. Fig. 2. Effects of methadone versus nicotine on $^{86}Rb^+$ efflux from KXα3β4R2 cells. $^{86}Rb^+$ efflux as measured as described under *Experimental Procedures*. Cells were loaded with $^{86}Rb^+$and then exposed for 2

min to buffer alone (to measure basal release), or buffer containing methadone at the concentration, shown. 100 μM nicotine or 100 μM nicotine plus 200 μM methadone. The $^{86}Rb^{+}$ efflux was response was expressed as a percentage of $^{86}Rb^{+}$loaded. Data shown in Fig. 2 are the mean ± standard error of four independent determinations. As shown in Fig. 2, at concentrations up to 1 mM, methadone did not increase $^{86}Rb^{+}$ efflux from KXα3β4R2 cells. In parallel assays, however, 100 μM nicotine stimulated $^{86}Rb^{+}$ efflux approximately 10-fold over basal levels, and this stimulation was completely blocked by 200 μM methadone. Thus demonstrating the blocking of α3β4 by methadone.

Potency of Methadone and Its Enantiomers in Inhibiting Nicotine-Stimulated $^{86}Rb^{+}$ Efflux from KXα3β4R2 Cells. The potencies of racemic methadone and its enantiomers as antagonists of the nAChRs were examined by measuring $^{86}Rb^{+}$efflux stimulated by 100 μM nicotine in the presence of increasing concentrations of the compounds. Cells were loaded with and then exposed for 2 min to buffer alone (basal release) or buffer containing 100 μM nicotine in the absence or presence of racemic methadone or one of the methadone enantiomers at the concentrations shown. $^{86}Rb^{+}$efflux was expressed as a percentage of $^{86}Rb^{+}$loaded, and control values were defined as $^{86}Rb^{+}$ efflux stimulated by 100 μM nicotine in the absence of methadone. Inhibition curves shown in Fig. 3 are from a single experiment measured in quadruplicate. See Table 1 for mean and standard error of the IC_{50} values. As illustrated in Fig. 3, racemic methadone potently inhibited nicotine-stimulated $^{86}Rb^{+}$efflux in a concentration-dependent manner with an IC_{50} of approximately 2 μM. Moreover, (+)-methadone and (-)-methadone inhibited the, function of these receptors with similar potencies (Fig. 3; Table 1).

TABLE 1 lists the inhibitory properties of enantiomers of methadone and compounds of the present invention on nicotine-stimulated $^{86}Rb^{+}$ efflux from KXα3β4R2 cells. IC_{50} values were calculated front inhibition curves in which $^{86}Rb^{+}$ efflux was stimulated by 100 μM nicotine, as described under *Experimental Procedures*. Mecamylamine, a standard nAChR antagonist, was included for comparison. Data shown are the mean ± standard error of three to six independent measurements.

Low Affinities of Methadone for nAChR Agonist Binding Sites. The ability of methadone to compete for α3β4 receptor agonist recognition sites labeled by [^{3}H]EB in membranes from KXα3β4R2 cells was examined. Binding assays were carried out as described under *Experimental Procedures* using 323 pM [^{3}H]EB. The K_i value for nicotine was 559 nM. The K_i values for methadone and mecamylamine cannot be estimated because there was less than 50% inhibition even at the highest concentration used (1 mM). As shown in Fig. 4 methadone does not compete effectively for [^{3}H]EB binding sites. Mecamylamine is shown for

comparison. Thus, even at the highest concentration used (1mM), methadone inhibited less than 50% of [^{3}H]EB binding to α3β4 receptors. This was comparable to the weak binding potency of mecamylamine. In parallel assays carried out as positive controls, nicotine competed effectively for the agonist binding sites of α3β4 receptors, yielding a dissociation constant (K_i) of 560 nM, which is similar to that previously reported in these cells (Xiao et al., 1998). Methadone's very low affinity for the agonist recognition sites of α3β4 receptors contrasts with its high potency in blocking receptor function (IC_{50} of about 2μM) and suggests a noncompetitive mechanism of receptor antagonism.

TABLE 1

Drug	IC_{50}
(+)-Mehtadone	μM
(-)-Methadone	1.9 ± 0.2
(+)-Methadone	2.5 ± 0.2
(-)-Methadone	2.0 ± 0.3
(+)-EDDP	0.4 ± 0.2
(-)-EDDP[a]	0.4 ± 0.1[a]
(+)-EMDP	5.8 ± 1.0
(-)-EMDP	6.3 ± 0.7
Propoxyphene	2.7 ± 0.4
Norpropoxyphene	1.8 ± 0.1
LAAM	2.5 ± 0.4
Mecamylamine	1.1 ± 0.2
Dextromethorphan	8.9 ± 1.1
Dextrorphan	29.6 ± 5.7
Mecamylamine	1.0 ± 0.04
MK-801	26.6 ± 9.6

[a]The IC_{50} value for (-)-EDDP significantly lower than that for mecamylamine ($p < 0.02$).

Noncompetitive Block of nAChR Function by Methadone. To definitively identify the type of receptor blockade by methadone, we examined its effect on concentration-response curves for receptor activation by nicotine. $^{86}Rb^+$ efflux was measured as described under

Experimental Procedures. Cells were loaded with $^{86}Rb^+$ and then exposed to buffer containing increasing concentrations of nicotine for 2 min in the absence (control) or presence of 1 μM methadone. The $^{86}Rb^+$ efflux was calculated as a percentage of $^{86}Rb^+$ loaded, and the E_{max} was defined as the maximum response in the absence of methadone. The curves shown are from a single experiment measured in quadruplicate. The EC_{50} Values in the absence and presence of methadone were 28.8 ± 1.2 and 21.3 ± 2.1 μM, respectively (mean ± standard error from four independent experiments). The E_{max}, value (mean ± standard error) in the presence of 1 μM methadone was 63 ± 2% of control values. Both the EC_{max} ($p < 0.05$) and E_{max} values ($p < 0.01$) in the presence of methadone are, significantly different from control values As shown in Fig. 5, in the presence of 1 μM methadone, the maximum $^{86}Rb^+$efflux stimulated by nicotine (E_{max}) was markedly reduced, but the EC_{50} for nicotine was altered only slightly, if at all. This result indicates that methadone does, in fact, block α3β4 nAChR function primarily by a noncompetitive mechanism.

Inhibitory Effects of Methadone Metabolites and Structural Analogs on $^{86}Rb^+$ Efflux from KXα3β4R2 Cells. We tested seven compounds related to methadone, including its metabolites and structural analogs, for their agonist and antagonist effects on $^{86}Rb^+$ efflux from KXα3β4R2 cells At concentrations up to 100 μM, none of these compounds increased $^{86}Rb^+$ efflux (data not shown).

Effects of Methadone and Related Drugs on nAChRs

However, all of the compounds tested here were relatively potent blockers of nicotine-stimulated $^{86}Rb^+$ efflux (See Table 1). Thus, the long-acting methadone analog LAAM as well as propoxyphene and norpropoxyphene were about as potent as methadone in blocking this α3β4 receptor-mediated response. The methadone metabolite EDDP was even more potent; in fact, EDDP appears to be one of the most potent nAChR antagonists that has been reported, being about 5 times more potent than methadone and about twice as potent as mecamylamine (Fig. 6; Table 1). Furthermore, like methadone, the two enantiomers of the metabolites were equipotent in blocking α3β4 nAChR (Table 1), although in these studies the difference in IC_{50} values between (-)-EDDP and mecamylamine was statistically significant ($p < 0.02$), while that for (+)-EDDP was not ($0.05 < p < 0.1$).

Fig. 6 Shows the comparison of the inhibition of nicotine-stimulated $^{86}Rb^+$ efflux from KXα3β4R2 cells by methadone, (+)-EDDP, LAAM, and mecamylamine. $^{86}Rb^+$ efflux was measured as described under *Experimental Procedures*. Cells were loaded with $^{86}Rb^+$ and then exposed for 2 min to buffer alone (basal release) or buffer containing 100 μM nicotine in the absence or presence of racemic methadone, (+)-EDDP, LAAM, or mecamylamine at the

concentrations shown. $^{86}Rb^+$ efflux was expressed as percentage of $^{86}Rb^+$ loaded and control values were defined as $^{86}Rb^+$ efflux stimulated by 100 μM nicotine in the absence of methadone.

Noncompetitive Block of nAChR Function by Methadone Metabolites and Structural Analogs. None of the compounds examined here competed effectively for [^{3}H]EB binding sites), suggesting that, like methadone, they block receptor function via a noncompetitive mechanism. To examine this more directly, the effects of (+)-EDDP and LAAM on concentration-response curves for receptor activation by nicotine were examined. $^{86}Rb^+$ efflux was measured as described under Experimental Procedure. Cells were loaded with $^{86}Rb^+$ and then exposed to buffer containing increasing concentrations of nicotine for 2 min in the absence (control) or presence of 0.5 μM EDDP of 3 μM LAAM. The $^{86}Rb^+$ efflux was calculated as a percentage of $^{86}Rb^+$ loaded, and the EC_{50} was defined as the maximum response in the absence of antagonists. The curves shown are from a single experiment measured in quadruplicate. The EC_{50} values for nicotine-stimulated $^{86}Rb^+$ efflux in the control cells, in the presence of 0.5 μM (+)EDDP, and in the presence of 3μ M LAAM were, respectively, 28.2 ± 1.5, 25.5 ± 1.5, and 18.8 ± 1.4 μM*. The E_{max}, values in the presence of 0.5 μM (+)-EDDP and 3μM LAAM were, respectively 60 ± 3** and 44 ± 5%** of control. Values are mean ± standard error from three independent experiments. The values that were significantly different from values of control are indicated by *$p < 0.05$ and **$p < 0.01$, respectively. As shown in Fig. 7, both of these compounds acted as noncompetitive blockers of α3β4 nicotinic receptors.

Discussion

We investigated the effects of the enantiomers of methadone and its metabolites as well as three structural analogs of methadone on the function of rat α3β4 nAChRs stably expressed in KXα3β4R2 cells. All of these compounds inhibited nicotine-stimulated ^{86}Rb efflux in a concentration-dependent manner and with relatively high potencies, comparable with that of mecamylamine. In particular, EDDP, the major oxidative metabolite of methadone, with an IC_{50} of about 0.4 μM, is one of the most potent nicotinic antagonists that has been reported.

A noncompetitive mechanism of nAChR blockade by methadone, EDDP, and LAMM is clearly indicated by the marked decrease in the maximum receptor-mediated response without a substantial change in the EC_{50} value for nicotine-stimulated $^{86}Rb^+$ efflux in the presence of these compounds. A noncompetitive mechanism is also consistent with the observation that neither methadone, its metabolites, nor its structural analogs compared effectively for [^{3}H]EB binding sites, which represent the agonist recognition site of the receptor. Taken together, these data indicate that all of these compounds most likely block within the α3β4 nAChR channel. There also appeared to be a slight but statistically significant decrease in

the EC_{50} value for nicotine-stimulated $^{86}Rb^{+}$ efflux in the presence of methadone and LAAM, implying that these drugs might actually increase the potency of nicotine at the receptor. Although it is very probable that the small difference in nicotine's EC_{50} values represents a statistical artifact, we cannot rule out an allosteric effect.

The (+)-and (-)-enantiomers of methadone and its metabolites are equipotent in blocking nAChR. This is in contrast to methadone's agonist actions at opiate receptors, which are ascribed almost entirely to its (-)-enantiomer. Therefore, the high potency of the (+)-enantiomers of methadone and its metabolites should allow blockade of nicotinic receptors without necessarily stimulating opiate receptors. This could then permit these (+)-enantiomers to be used in conditions where blockade of neuronal nicotinic receptors might be beneficial. For example, receptor blockade by mecamylamine is reported to aid in smoking cessation (Rose et al., 1994, 1998), and the most potent of the methadone metabolites is approximately twice as potent as mecamylamine. In addition, nicotinic receptors are thought to play a potentially important role in some analgesia pathways (Flores, 2000). Although analgesia has most often been associated with nicotinic agonists, these actions are incompletely understood, and it is possible that nicotinic antagonists can also contribute to analgesia (Hamann and Martin, 1992). If this were the case for methadone and its metabolites, their analgesic effect through nicotinic mechanisms would perhaps be additive to analgesia mechanisms mediated by opiate receptors. This would be particularly useful where tolerance to opiates and/or ceiling effects are issues. In fact, both dextromethorphan, which blocks NMDA and nicotinic receptors, and (+)-methadone are reported to attenuate the development of tolerance to morphine analgesia (Elliott et al., 1994; Davis and Inturrisi, 1999).

The plasma concentration of methadone following a single dose is approximately 0.25 μM (Inturrisi and Verebely, 1972) and the steady-state concentration in patients taking methadone chronically can exceed 1 μM (de Vos et al., 1995; Alburges et al., 1996; Dyer et al., 1999). At these concentrations, methadone could be expected to produce significant blockade of α3β4 nicotinic receptors. The steady-state plasma concentration of the more potent EDDP is usually much lower, but the peak concentration following administration of methadone can approach 0.2 μM (de Vos et al., 1995).

It should also be noted that (+)-methadone blocks NMDA receptor channels with potencies similar to, although slightly lower than, those found here at nicotinic receptors (Gorman et al., 1997; Stringer et al., 2000). Methadone's block of NMDA receptors also has been linked to its analgesic actions (Shimoyama et al., 1997; Davis and Inturrisi, 1999), and particularly to its potential usefulness for treating chronic and/or neuropathic pain (Elliott et al.,

1995; Hewitt, 2000; Stringer et al., 2000). In addition, methadone's possible attenuation of morphine tolerance may involve NMDA receptors (Gorman et al., 1997; Davis and Inturrisi, 1999). In this regard, however, the block of nicotinic receptors by EDDP and (+)-methadone might also contribute directly to analgesic actions and even to the attenuation of morphine tolerance. Thus, it is possible that methadone and its metabolites can affect three different neurotransmission systems that have been associated with analgesia pathways and tolerance to opiates.

Accordingly, the compounds of the present invention block α3β4 nicotinic cholinergic receptors by a noncompetitive mechanism consistent with channel blockade. Both the (+)- and (-)-enantiomers of methadone and its metabolites are active; therefore, the high potency of the (+)-enantiomers of these compounds, particularly EDDP, in blocking nicotinic receptors should allow them to be used as probes of nicotinic receptors without affecting opiate receptors.

The Compounds

In describing the compounds, the following definitions are used, each of which includes all possible geometric, racemic, diasteriomeric, and enantiomeric forms thereof.:

The term alkyl includes branched and straight chain, saturated and unsaturated, substituted and unsubstituted alkyl groups. Examples of alkyls include methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, etc.


The term alkenyl refers to an ethylenically unsaturated hyrdocarbon group, straight or branched, which may be substituted or unsubstituted.

The term alkynyl refers to a straight or branched hydrocarbon group having 1 or 2 acetylenic bonds, which may be substituted or unsubstituted.


The term aryl refers to phenyl, which may be substituted with 1-5 substituents.

The term azaaromatic refers to an aromatic ring containing 1-3 nitrogen atoms, which may be substituted with 1-5 substituents.

The general structure of these compounds is set forth as Formulae I and II below, and include all possible geometric, racemic, diasteriomeric, and enantiomeric forms thereof:



Formula I



Formula II

where:

R^1 is H, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkenyl, and aryl or azaaromatic having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, and aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso;

R^2 is hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkene, or (C_2-C_6)alkynyl, and in Formula I, R^2 may also be selected from O= or HN=;

R^3 is selected from hydrogen, (C_1-C6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6) alkenyl, aryl, and aryl(C_1-C_6)alkyl;

Preferably, R^3 is methyl or ethyl;






R^4 is C_1-C_6 alkyl, and (C_3-C_6)cycloalkyl; and







R^5 is aryl or azaaromatic having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, and aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso and may form a bond to R^1 to result in a conjugated ring system.







The compounds may be in the form of pharmaceutically acceptable salts, including but not limited to inorganic acid addition salts such as hydrochloride, hydrobromide, sulfate, phosphate and nitrate; organic acid addition salts such as acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, salicylate, p-toluenesulfonate, benzenesulfonate, and ascorbate; salts with acidic amino acids such as aspartate and glutamate; the salts may in some cases by hydrates or solvates with







alcohols and other solvents. Salt forms can be prepared by mixing the appropriate amine with the acid in a conventional solvent, with or without alcohols or water.







More specifically, the following compounds are contemplated:







Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 1 (trans)	C	phenyl	CH_2CH_3	H	CH_3	phenyl	I/1
 2 (cis)	C	phenyl	CH_2CH_3	H	CH_3	phenyl	I/1
 3 (trans)	C	phenyl	CH_2CH_3	CH_3	CH_3	phenyl	I/1
 4 (trans)	C	phenyl	CH2CH3	CH_3	CH_3	phenyl	I/1
 5	C	phenyl	=O	H	CH_3	phenyl	I/1






Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 6	C	phenyl	=O	H	CH_3	phenyl	I/1
 7	C	phenyl	=O	CH_3	CH_3	phenyl	I/1
 8	C	phenyl	=O	CH_3	CH_3	phenyl	I/1
 9	C	phenyl	=NH	H	CH_3	phenyl	I/1
 10	C	phenyl	=NH	H	CH_3	phenyl	I/1
 11	C	phenyl	$=NCH_3$	H	CH_3	phenyl	I/1

Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 12	C	phenyl	$=NCH_3$	H	CH_3	phenyl	I/1
 13	C	phenyl	$-CCH_3CH_2$	H	CH_3	phenyl	II/1
 14	C	phenyl	$-CCH_3CH_2$	CH_3	CH_3	phenyl	II/1
 15	C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II/1
 16	C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II/1
 17	C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II/1

Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 18	C	phenyl	-$CH(CH_3)_2$	CH_3	CH_3	phenyl	II/1
 19 TRANS	C	H	-CH_2CH_3	H	CH_3	phenyl	II/2
 20 CIS	C	H	-CH_2CH_3	H	CH_3	phenyl	II/2
 21 TRANS	C	H	-CH_2CH_3	CH_3	CH_3	phenyl	II/2
 22 CIS	C	H	-CH_2CH_3	CH_3	CH_3	phenyl	II/2
 23TRANS	N	H	-CH_2CH_3	H	CH_3	3-pyridinyl	II/2


Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 24 CIS	N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II/2
 25 TRANS	N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II/2
 26 CIS	N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II/2
 27TRANS	N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II/2
 28 CIS	N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II/2
 29 TRANS	N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II/2

Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 30 CIS	N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II/2
 31	N	phenyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II/1
 32	N	pyridinyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II/1
 33	N	phenyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II/1
 34	N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II/1
 35	N	phenyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II/1

Structure	X	R^1	R^2	R^3	R^4	R^5	Formula/ Series
 36	N	pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II/1
 37	N	4-chloro-3-pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II/1
 38	N	phenyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II/1
 39	N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II/1
 40	N	4-chloro-3-pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II/1

* =N indicates that there is a double bond in the five membered ring between R^3 and the carbon carrying R^2.

Compounds where R^5 bonds to R^1 such as those set forth below may also be used, and can be made through simple alterations to the synthesis of the above compounds.



where

X and Y are independently selected from the group consisting of C and N;

R^3 is as set forth above;

R^6 is independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, and aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino.

Exemplary Syntheses

Figs. 8 and 9 show some exemplary synthesis reactions that may be used to produce these compounds. The compounds disclosed in the syntheses include all possible geometric, racemic, diasteriomeric, and enantiomeric forms unless otherwise noted. Structures listed in parentheses correspond to those listed in the above table. Those skilled in the art will recognize that these compounds may be formed by other sythesis reactions, and that simple modifications to these syntheses will produce similar products, all of which are considered within the scope of this invention.

Series 1

Fig. 8 shows the basic synthesis reaction, which produces Compound (f) (Structures 9 and 10). First, bromobenzene (a), or bromoheterocycle where X is a heteroatom at any position, is mixed with CH_3CN and KNH_2 in liquid ammonia to yield (b). Which is then mixed with a second bromobenzene or heterocycle, where Y is a heteroatom selected independently of X at any location, with Br_2 at 105-110°C to yield the diphenyl cyanide (c). This product is then reacted in a basic solution, with t-butylenemethoxylate to yield compound (d). Compound (d) is

reacted with $SOCl_2$ and ammonia to produce compound (f), the amidino analogs. Those skilled in the art will recognize that, in light of this synthesis, compounds 11 and 12, and other variations, may be made simply by similar methods.

Synthesis of compounds (g), and (j)

The compound (f) is further reacted with 1.2N HCl with $NaNO_2$ for about 1 hour to yield a compound (g), (Structures 5 and 6). Reaction of this mixture with LAH/THF yields compound (j), which also may be used in the methods disclosed herein.

Synthesis of compounds (h) and (k)

Beginning where the reaction left off with compound (g), above, further reaction with CH_3I substitutes a methyl group to the nitrogen of the five membered ring to yield compound (h) (Structures 7 and 8). Compound (k) is achieved by reacting this mixture with LAH/THF.

Synthesis of compounds (i), (l), (m), (n), (o), and (p)

Picking up the reaction at the formation of compound (h), further reaction with EtLi to open the double bonded oxygen yields compound (i) (Structures 33 and 34). Compound (i) is then the basis for three other chains of reaction.

Compound (l) is formed by reacting compound (i) with MCPBA and $CHCl_3$ for 12 hours at 0°C. Compound (m) (Structures 1 and 2) is then formed by reacting this with $NaBH_4$.

Compound (n) (Structures 3 and 4) are produced by reacting compound (i) with NaBH4.

Compound (i) is reacted with HCHO and CH_3OH to produce compound (o) (Structure 14), which is then reacted with H_2 and Pd-C to yield Compound (p) (Structures 16, 18).

Series 2

The synthesis reaction for series two is identical to that for series one except that the second step of mixing a second bromobenzene (b_2), or bromoheterocycle, is omitted. Similar mono-phenyl compounds are thus produced. Fig. 9 sets out the synthesis reaction for series two. Parrallel compounds to those of Series 1 are indicated with references characters with the subscript 2.

Analgesia and Abuse Deterrance

To confirm their suspicions that the compounds of the present invention, do in fact have an analgesic effect, the inventors experimented with mice. Fig. 10 shows the results of an experiment conducted on naive, adult, Swiss-Webster mice. Each enantiomer of EDDP, in 40μg doses, was administered intracerebrally to the mice. The animals were monitored for baseline sensitivity using the warm-water tail-withdrawal nociception assay and the latency to tail withdrawal was monitored as a measurement of analgesia. The results demonstrate that tail withdrawal latency increased with the administration of either enantiomer of EDDP. Thus, it is

clear that the d-methadone metabolite EDDP has significant analgesic effect. Likewise, the metabolite EMDP and the structural analogs of both EDDP and EMDP are expected to do the same. Figs 11 and 12 illustrate the effect of EDDP concentration on the inhibition of nicotine activated currents, which is one explanation for the analgesic effect.

As discussed in detail above, the inventors believe the d-methadone metabolites and their analogs block the nicotinic α3β4 receptor. Recently, it has been reported that dextromethorphan and dextrorphan, α3β4 blockers, actually deter abuse of abusive substances. Glick et al. report a decrease in self-administration of each of morphine, methamphetamine, and nicotine in rats when exposed to 5-30 mg/kg of these specific α3β4 blockers. Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA; Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats; Eur J Pharmacol. 2001 Jun 22;422(1-3):87-90. Because of their discovery that the d-methadone metabolites and their structural analogs are α3β4 blockers, the current inventors contemplate that the d-methadone metabolites and their analogs also have such deterrent affects.

The inventors do not wish to be bound by this theory, but believe that the d-methadone metabolites or structural analogs interfere with the reward component of the abusive substance. The reward component is often thought of as the euphoric effect, as inducing drug seeking behavior. The administration of the d-methadone metabolites or structural analogs interferes with these effects, and deters abuse as a result. Such administration will aid in smoking cessation and deter abuse of more hard core substance.

Accordingly, administration of the d-methadone metabolites or their structural analogs can actually deter abuse of abusive substances from the opioids to nicotine.

Administration

The compounds of the present invention may be administered to patients in effective amounts or effective doses to alleviate pain and/or deter abuse of an abusive substance. In another embodiment, the compounds are administered in combination with abusive substances, particularly opioids or other analgesics, in a single pharmaceutical composition. In this scenario, the compounds of the present invention contribute to the analgesic effect while also deterring the abuse of the companion compound. Thus, patients benefit from the added analgesic effect of the compound, while gaining the added benefit of reduced potential for abuse. In another embodiment, the compounds of the present invention are administered independently of an abusive substance to induce analgesia. In yet another embodiment, the independent administration of the compounds serves to deter abuse of a separately administered abusive substance.

By "effective amount," "therapeutic amount," or "effective dose" is meant that the amount sufficient to elicit the desired pharmacological or therapeutic effect, thus resulting in effective prevention or treatment of the condition or disorder. Thus, when treating a CNS disorder, an effective amount of compound is that amount sufficient to pass across the blood-brain barrier of the subject to interact with relevant receptor sites in the brain of the subject. Prevention of the condition or disorder is manifested by delaying the onset of the symptoms of the condition or disorder. Treatment of the condition or disorder is manifested by a decrease in the symptoms associated with the condition or disorder, or an amelioration of the recurrence of the symptoms of the condition of disorder.

The effective dose can vary, depending upon factors such as the condition of the patient, the severity of the symptoms of the disorder, age, weight, metabolic status, concurrent medications, and the manner in which the pharmaceutical composition is administered. Typically, the effective dose of compounds generally requires administering the compound in an amount of about 0.1 to 500 mg/kg of the subject's weight. In an embodiment of the present invention, a dose of about 0.1 to about 300 mg/kg is administered per day indefinitely or until symptoms associated with the condition or disorder cease. Preferably, about 1.0 to 50 mg/kg body weight is administered per day. The required dose is less when administered parenterally.

Those skilled in the art will recognize that the compounds of the present invention may be incorporated with suitable pharmaceutical agents to form a pharmaceutical composition for appropriate administration. Such compositions may limit the active ingredient to a compound of the present invention, or may optionally include other active ingredients or multiple compounds of the present invention.

Pharmaceutical Compositions

The compounds of the present invention are useful in pharmaceutical compositions for systemic administration to mammals including humans as a single agent, or as a primary or adjunct agent with any other medication, chemical, drug or non-drug therapy, or combination thereof. In addition to the compounds, a pharmaceutical composition according to the invention may include one or more pharmaceutical agents including carriers, excipients, actives, fillers, etc.

Administration of the compounds or pharmaceutically acceptable salts or complexes thereof can be employed acutely, or as a single dose, or administered intermittently, or on a regular schedule of unspecified duration, or by continuous infusion of unspecified duration, by an acceptable route of administration including, but not limited to, the oral, buccal, intranasal,

pulmonary, transdermal, rectal, vaginal, intradermal, intrathecal, intravenous, intramuscular, and/or subcutaneous routes.

The pharmaceutical preparations can be employed in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile and parenteral solutions, or suspensions, sterile and non-parenteral solutions or suspensions, oral solutions or suspensions, oil in water or water in oil emulsions and the like, containing suitable quantities of an active ingredient. Topical application can be in the form of ointments, creams, lotions, jellies, sprays, douches, and the like. For oral administration either solid or fluid unit dosage forms can be prepared with the compounds of the invention.

Either fluid or solid unit dosage forms can be readily prepared for oral administration. For example, the compounds can be mixed with conventional ingredients such as dicalciumphosphate, magnesium aluminum silicate, magnesium stearate, calcium sulfate, starch, talc, lactose, acacia, methylcellulose and functionally similar materials as pharmaceutical excipients or carriers. A sustained release formulation may optionally be used. Capsules may be formulated by mixing the compound with a pharmaceutical diluent which is inert and inserting this mixture into a hard gelatin capsule having the appropriate size. If soft capsules are desired, a slurry (or other dispersion) of the compound, with an acceptable vegetable, light petroleum or other inert oil can be encapsulated by machine into a gelatin capsule.

Suspensions, syrups, and elixirs may be used for oral administration of fluid unit dosage forms. A fluid preparation including oil may be used for oil soluble forms. A vegetable oil, such as corn oil, peanut oil, or safflower oil, for example, together with flavoring agents, sweeteners, and any preservatives produces an acceptable fluid preparation. A surfactant may be added to water to form syrup for fluid dosages. Hydro-alcoholic pharmaceutical preparations may be used that have an acceptable sweetener, such as sugar, saccharine, or a biological sweetener and a flavoring agent in the form of an elixir.

Pharmaceutical compositions for parental and suppository administration can also be obtained using techniques standard in the art. Another preferred use of these compounds is in a transdermal parenteral pharmaceutical preparation in a mammal such as a human.


The above and other compounds can be present in the reservoir alone, or in combination form with pharmaceutical carriers. The pharmaceutical carriers acceptable for the purpose of this invention are the art known carriers that do not adversely affect the drug, the host, or the material comprising the drug delivery device. Suitable pharmaceutical carriers include sterile water, saline, dextrose, dextrose in water or saline, condensation products of castor oil and ethylene oxide combining about 30 to about 35 moles of ethylene oxide per mole of castor oil,

liquid acid, lower alkanols, oils (such as corn oil, peanut oil, sesame oil and the like), with emulsifiers such as mono- or di- glyceride of a fatty acid or a phosphatide (e.g., lecithin and the like), glycols, polyalkyne glycols, aqueous media in the presence of a suspending agent (for example, sodium carboxymethylcellulose), sodium alginate, poly(vinylpyrolidone), and the like (alone or with suitable dispensing agents such as lecithin), or polyoxyethylene stearate and the like. The carrier may also contain adjuvants such as preserving, stabilizing, wetting, emulsifying agents and the like together with the penetration enhancer of this invention.


Although the invention has been described in connection with specific forms thereof, those skilled in the art will appreciate that a wide variety of equivalents may be substituted for the specified elements described herein without departing from the scope and spirit of this invention as described in the claims below.

What is claimed is:

1. A method of inducing analgesia comprising administering to a patient, an analgesia inducing amount of a composition comprising a compound selected from one of Formula I, and Formula II and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkenyl, aryl, and azaaromatic;

R^2 is selected from hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkene, and (C_2-C_6)alkynyl, and in Formula I, R^2 may also be selected from O= or HN=;

R^3 is selected from hydrogen, (C_1-C6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6) alkenyl, aryl, and aryl(C_1-C_6)alkyl;

R^4 is selected from (C_1-C_6) alkyl, and (C_3-C_6)cycloalkyl; and

R^5 is aryl or azaaromatic and may include a bond to R^1 to result in a conjugated ring system.

2. The method of claim 1, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

3. The method of claim 1, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, and aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

4. The method of claim 1 wherein R^3 is methyl or ethyl.


5. The method of claim 1, wherein said compound is selected from the following group:

X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	CH2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$-CCH_3CH_2$	H	CH_3	phenyl	II
C	phenyl	$-CCH_3CH_2$	CH_3	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II


X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II.

6. The method of claim 1 wherein said analgesia inducing amount of a composition is sufficient to block nicotinic receptors to thereby induce analgesia.

7. A method of deterring abuse of abusive substances comprising administering to a patient, an abuse deterring amount of a composition including compound selected from one of Formula I, and Formula II and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkenyl, aryl and azaaromatic;

R^2 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkene, and $(C_2\text{-}C_6)$alkynyl, and in Formula I, R^2 may additionally be selected from O= or HN=;

R^3 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$ alkenyl, aryl, and aryl$(C_1\text{-}C_6)$alkyl;

R^4 is $(C_1\text{-}C_6)$ alkyl, and $(C_3\text{-}C_6)$cycloalkyl; and

R^5 is aryl or azaaromatic and may include a bond to R^1 to result in a conjugated ring system.

8. The method of claim 7, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, aryl$(C_1\text{-}C_6)$alkyl, N-methylamino, N,N-dimethylamino, carboxylate, $(C_1\text{-}C_3)$alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

9. The method of claim 7, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, and aryl$(C_1\text{-}C_6)$alkyl, N-

methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

10. The method of claim 7 wherein R^3 is methyl or ethyl.

11. The method of claim 7, wherein said compound is selected from the following group:


X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	CH2CH3	CH_3	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$-CCH_3CH_2$	H	CH_3	phenyl	II
C	phenyl	$-CCH_3CH_2$	CH_3	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II

X	R^1	R^2	R^3	R^4	R^5	Formula
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II.


12. The method of claim 7 wherein said amount of compound selected from one of Formula I, and Formula II and pharmaceutically acceptable salts is sufficient to block nicotinic receptors to thereby deter abuse of abusive substances.

5

13. A compound of selected from the group consisting of Formula I, Formula II, and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkenyl, aryl and azaaromatic;

R^2 is selected from hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkene, and (C_2-C_6)alkynyl, and in Formula I, R^2 may additionally be selected from O= or HN=;

R^3 is selected from hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, C_2-C_6 alkenyl, aryl, and aryl(C_1-C_6)alkyl;

R^4 is C_1-C_6 alkyl, and (C_3-C_6)cycloalkyl; and

R^5 is aryl or azaaromatic and may form a bond to R^1 to result in a conjugated ring system,

except compounds of Formula II where $R^5 = R^1$ = phenyl, R_2 is ethyl, R_4 is H, and R_3 is H or CH_3.

14. The compound of 13, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

15. The compound of claim 13, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group

consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

16. The compound of claim 13 wherein R^3 is methyl or ethyl.

17. The compound of claim 13, wherein said compound is selected from the following group:

X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	CH2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	=NCH_3	H	CH_3	phenyl	I
C	phenyl	=NCH_3	H	CH_3	phenyl	I
C	phenyl	-CCH_3CH_2	H	CH_3	phenyl	II
C	phenyl	-CCH_3CH_2	CH_3	CH_3	phenyl	II
C	phenyl	-$CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	-$CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	phenyl	-$CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	-$CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	H	-CH_2CH_3	H	CH_3	phenyl	II

X	R^1	R^2	R^3	R^4	R^5	Formula
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II.

18. The compound according to claim 13, wherein said analogs are in the form of pharmaceutically acceptable salts.

19. The compound of claim 18, wherein said pharmaceutically acceptable salts are inorganic acid addition salts, organic acid addition salts, salts with acidic amino acids, and hydrates or solvates thereof with alcohols and other solvents.

20. The compound of claim 19, wherein said analog is an inorganic acid addition salt selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate and nitrate.


21. The compound of claim 19, wherein said analog is an organic acid addition salts salt selected from the group consisting of acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, salicylate, p-toluenesulfonate, benzenesulfonate, and ascorbate.

22. The compound of claim 19, wherein said analog is a salt with acidic amino acids selected from the group consisting of aspartate and glutamate.


23. A pharmaceutical composition comprising:

a pharmaceutically acceptable agents; and

a compound selected from one of Formula I and Formula II, and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkenyl, aryl and azaaromatic;

R^2 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkene, and $(C_2\text{-}C_6)$alkynyl, and in Formula I, R^2 may additionally be selected from O= or HN=;

R^3 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$ alkenyl, aryl, and aryl$(C_1\text{-}C_6)$alkyl;

R^4 is $(C_1\text{-}C_6)$ alkyl, and $(C_3\text{-}C_6)$cycloalkyl; and R^5 is aryl or azaaromatic and may form a bond to R^1 to result in a conjugated ring system; and

wherein said amount is sufficient to induce anlgesia and/or deter abuse of abusive substances.

24. The composition of claim 23, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

25. The composition of claim 23, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, aryl, aryl(C_1-C_6)alkyl, N-methylamino, N,N-dimethylamino, carboxylate, (C_1-C_3)alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

26. The composition of claim 23 wherein R^3 is methyl or ethyl.

27. The composition of claim 23, wherein said compound is selected from the following group:

X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	H	CH_3	phenyl	I
C	phenyl	CH_2CH_3	CH_3	CH_3	phenyl	I
C	phenyl	$CH2CH_3$	CH_3	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	H	CH_3	phenyl	I
C	phenyl	=O	CH_3	CH_3	phenyl	I

X	R^1	R^2	R^3	R^4	R^5	Formula
C	phenyl	=O	CH_3	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	=NH	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$=NCH_3$	H	CH_3	phenyl	I
C	phenyl	$-CCH_3CH_2$	H	CH_3	phenyl	II
C	phenyl	$-CCH_3CH_2$	CH_3	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	H	CH_3	phenyl	II
C	phenyl	$-CH(CH_3)_2$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	H	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
C	H	$-CH_2CH_3$	CH_3	CH_3	phenyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	H	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	pyridinyl	II
N	phenyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	H	CH_3	4-chloro-3-pyridinyl	II
N	phenyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II
N	pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II

X	R^1	R^2	R^3	R^4	R^5	Formula
N	4-chloro-3-pyridinyl	$-CH_2CH_3$	CH_3	CH_3	4-chloro-3-pyridinyl	II.

28. The pharmaceutical composition according to claim 23, wherein said analogs are in the form of pharmaceutically acceptable salts.

29. The pharmaceutical composition of claim 28, wherein said pharmaceutically acceptable salts are inorganic acid addition salts, organic acid addition salts, salts with acidic amino acids, and hydrates or solvates thereof with alcohols and other solvents.

30. The pharmaceutical composition of claim 29, wherein said analog is an inorganic acid addition salt selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate and nitrate.

31. The pharmaceutical composition of claim 29, wherein said analog is an organic acid addition salts salt selected from the group consisting of acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, salicylate, p-toluenesulfonate, benzenesulfonate, and ascorbate.

32. The pharmaceutical composition of claim 29, wherein said analog is a salt with acidic amino acids selected from the group consisting of aspartate and glutamate.

ABSTRACT

A method for inducing analgesia and/or inhibiting abuse of abusive substances includes administration of d-methadone metabolites or their structural analogs. The d-methadone metabolites, EMDP and EDDP, and their structural analogs may be incorporated into a suitable pharmaceutical composition for administration to patients. The invention includes the method itself, certain structural analogs, and pharmaceutical compositions for use in accordance with the method.



Methadone
LAAM
EDDP
EMDP
Propoxyphene
Norpropoxyphene
Mecamylamine

FIG 1



50
40
30
20
10
0
$^{86}Rb^+$ efflux
(% of $^{86}Rb^+$ loaded)
Methadone 0 1 10 100 1000 0 200 μM
Nicotine 0 0 0 0 0 100 100 μM

FIG 2



Stimulated $^{86}Rb^{+}$ efflux (% of control)
100
75
50
25
0
Methadone
(+)-Methadone
(-)-Methadone
-8
-7
-6
-5
-4
-3
log [compound] (M)

FIG 3



% of Specific Binding
100
75
50
25
0
Nicotine
Methadone
Mecamylamine
-8
-7
-6
-5
-4
-3
log [compound] (M)

FIG 4



Stimulated $^{86}Rb^{+}$ efflux (% of E_{max})
100
75
50
25
0
Control
1 μM methadone
-6
-5
-4
-3
log [nicotine] (M)

FIG. 5



Stimulated $^{86}Rb^{+}$ efflux
(% of control)
100
75
50
25
0
(+)-EDDP
Mecamylamine
Methadone
LAAM
-8
-7
-6
-5
-4
-3
log [compound] (M)

FIG 6



Xiao et al.
Stimulated $^{86}Rb^{+}$ Efflux (% of E_{max})
100
75
50
25
0
Control
0.5 μM (+)-EDDP
3 μM LAAM
-6
-5
-4
-3
log [nicotine] (M)
370

FIG 7



(a)
(b)
(c)
(d)
(e)
(f)
1.2 N HCl
NaNO2/ 1 h
(g)
(h)
(i)
→ (cont.)
LAH/THF
LAH/THF
NaBH4
MCPBA
CHCl3
12h 0°C
(j)
(k)
(n)
(l)
NaBH4
(m)

FIG. 8




Fig. 8 (cont.)



(a2)
(b2)
(c2)
(d2)
(e2)
(f2)
(g2)
(h2)
(i2)
(j2)
(k2)
(l2)
(m2)
(n2)
CH3I
LAH/THF
LAH/THF
MCPBA
CHCl3
NaBH4
NaBH4

Fig. 9



EDDP Analgesia
Change from baseline (sec)
0
2
4
6
8
15
30
60
90
Time (min)
(+)EDDP
(-)EDDP
SAL

FIG. 10



30 μM Nicotine
+ 0.01 μM EDDP
+ 0.1 μM EDDP
+ 0.5 μM EDDP
+ 5.0 μM EDDP
+ 100 μM EDDP
500pA
10 s

Fig. 11

Fig. 12.



100
75
50
25
0
% of Maximal Response
IC50 = 1.1µM
-9
-8
-7
-6
-5
-4
-3
Log [EDDP] (M)

Fig. 13




Hippocampus
Baseline
1 mM Glutamate
% Fractional Release
15
10
5
0
Control
3 μM
1 μM
10 μM
10 μM
100 μM
MK-801
d-Methadone
R(+)-EDDP
Treatment

Fig. 14


Striatum
Baseline
1 mM Glutamate
% Fractional Release
15
10
5
0
Control
3 μM
1 μM
10 μM
10 μM
100 μM
MK-801
d-Methadone
R(+)-EDDP
Treatment

U.S. Serial No. 10/501,692 filed 07/15/04 for Richard Smith-Carliss et al. entitled ANALGESICS AND METHODS OF USE

Dated: February 18, 2005 Docket No.: END-04-1182PCT-US

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DT07 Rec'd PCT/PTO 18 FEB 2005

RECEIVED

FEB 28 2005

IP DEPT.

Sir: Kindly date stamp this card and return it to the undersigned to evidence receipt of the enclosed Certificate of Mailing, $130.00 Check, Transmittal Letter, in duplicate and executed Combined Declaration, Power of Attorney and Petition (4 pages). Thank you.

TDC:rb

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/501,692	**Customer No. 035811**
Filed	: July 15, 2004	
PCT No.	: PCT/US02/27936	
PCT Filed	: August 29, 2002	
Inventors	: Richard Smith-Carliss	Docket: END041182PCTUS
	: Frank S. Caruso	
	: Peter Crooks	
	: Kenneth J. Kellar	
	: Yingxian Xiao	
Title	: ANALGESICS AND METHODS	
	: OF USE	Dated: February 18, 2005

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATION

37 C.F.R. §1.10

Express Mail Label No.: EV 548522778 US

Date of Deposit: February 18, 2005

Description of Contents: Postcard, $130.00 Check, Transmittal Letter, in duplicate and executed Combined Declaration, Power of Attorney and Petition (4 pages).

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR§1.10 on the date indicated above and is addressed to **Mail Stop PCT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rosemary Bell
(Typed or printed name of person mailing paper or fee)

Rosemary Bell
(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/501,692	**Customer No. 035811**
Filed	: July 15, 2004	
PCT No.	: PCT/US02/27936	
PCT Filed	: August 29, 2002	
Inventors	: Richard Smith-Carliss	Docket: END041182PCTUS
	: Frank S. Caruso	
	: Peter Crooks	
	: Kenneth J. Kellar	
	: Yingxian Xiao	
Title	: ANALGESICS AND METHODS	
	: OF USE	Dated: February 18, 2005

TRANSMITTAL LETTER

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We submit herewith the executed Combined Declaration, Power of Attorney and Petition and request that it be formally entered in the file of the case.

We enclose herewith our check in the amount of $130.00 comprising the surcharge for filing the Combined Declaration later than the date of actual filing of the application in the U.S. Patent & Trademark Office.

The Commissioner is authorized to charge any insufficiency or credit any overpayment to Deposit Account No. 50-2719. This authorization is made in duplicate.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750

TDC:rb
(215) 656-3381

Attorney Docket No. END041182PCTUS

☐ Original Application
☐ PCT National Application
U.S. Designated Office
☒ Continuation or Divisional Application
☐ Continuation-in-Part Application

COMBINED DECLARATION,
POWER OF ATTORNEY AND PETITION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ANALGESICS AND METHODS OF USE

☒ which is described in the specification and claims

☐ attached hereto.

☒ filed on July 15, 2004

Application Serial No. 10/501,692

and was amended on _____
(*if applicable*)

☐ which is described in International Application No. _____

filed _____ and as amended on

_____(if any),

which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Attorney Docket No. END041182PCTUS

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International Application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application(s) for patent or inventor's certificate or of any PCT International Application having a filing date before that of the application on which priority is claimed:

Number	Country	Date of Filing (day,month,year)	Priority Claimed
			☐ yes ☐ no
			☐ yes ☐ no
			☐ yes ☐ no
			☐ yes ☐ no
			☐ yes ☐ no

I hereby claim the benefit under Title 35, United States Code, §119(e) or §120 (as applicable) of any United States application(s) or §365(c) of any PCT International Application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International Application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112:

PCT/US02/27936	29 August 2002	
(Application Serial No.)	*(Filing Date)*	*(Status)(patented,pending,abandoned)*
60/315,530	29 August 2001	
(Application Serial No.)	*(Filing Date)*	*(Status)(patented,pending,abandoned)*

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered attorneys associated with Piper Rudnick LLP and listed under **Customer No. 035811** and the following registered attorneys to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Jerold I. Schneider	Reg. No. 24,765	Lisa K. Norton	Reg. No. 44,977
Steven B. Kelber	Reg. No. 30,073	Patrick R. Delaney	Reg. No. 45,338
T. Daniel Christenbury	Reg. No. 31,750	Steven A. Nash	Reg. No. 45,507
Paul A. Taufer	Reg. No. 35,703	Christopher W. Raimund	Reg. No. 47,258
Darius C. Gambino	Reg. No. 41,472	Ping Wang	Reg. No. 48,328
James M. Heintz	Reg. No. 41,828	Andrew A. Noble	Reg. No. 48,651
Perry E. Van Over	Reg. No. 42,197	James E. Bauersmith	Reg. No. 50,533
Paul Carango	Reg. No. 42,386		

SEND CORRESPONDENCE TO:	DIRECT TELEPHONE CALLS TO ATTORNEY OF RECORD AT:
Customer No. 035811, whose contact information is: IP Department of Piper Rudnick LLP One Liberty Place, Suite 4900 1650 Market Street Philadelphia, PA 19103	(215) 656-3300

Attorney Docket No. END041182PCTUS

I hereby petition for grant of a United States Letters Patent on this invention.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1. FULL NAME OF SOLE OR FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE
Richard Smith-Carliss	Richard Smith-Carliss	7/23/04
RESIDENCE	CITIZENSHIP	
West Chester, Pennsylvania	United States of America	
POST OFFICE ADDRESS		
621 Cricklewood Road, West Chester, PA 19382		
2. FULL NAME OF JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
Frank S. Caruso		
RESIDENCE	CITIZENSHIP	
Colts Necks, New Jersey	United States of America	
POST OFFICE ADDRESS		
2 Bowling Green, Colts Necks, NJ 07722-1300		
3. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
~~Peter Crooks~~ PETER A. CROOKS	Peter A Crooks	8/5/04
RESIDENCE	CITIZENSHIP	
~~Lexington, Kentucky~~ NICHOLASVILLE, KENTUCKY	United States of America	
POST OFFICE ADDRESS 409 WEST BRANNON RD, NICHOLASVILLE, KY 40356		
~~University of Kentucky, 501 B Pharmacy Building, Rose Street, Lexington, KY 40536-0082~~		
4. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
Kenneth J. Kellar		9/24/04
RESIDENCE	CITIZENSHIP	
Bethesda, Maryland	United States of America	
POST OFFICE ADDRESS		
7109 Braeburn Place, Bethesda, MD 20817		
5. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
Yingxian Xiao		9/24/04
RESIDENCE	CITIZENSHIP	
Potomac, Maryland	United States of America	
POST OFFICE ADDRESS		
11713 Tifton Drive, Potomac, MD 20854		
6. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
7. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

COMBINED DECLARATION, POWER OF ATTORNEY AND PETITION
(Page 3)

I hereby petition for grant of a United States Letters Patent on this invention.

Attorney Docket No. END0041182PCTUS

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1. FULL NAME OF SOLE OR FIRST INVENTOR Richard Smith-Carliss	INVENTOR'S SIGNATURE Richard Smith-Carliss	DATE 7/23/04
RESIDENCE West Chester, Pennsylvania	CITIZENSHIP United States of America	
POST OFFICE ADDRESS 621 Cricklewood Road, West Chester, PA 19382		
2. FULL NAME OF JOINT INVENTOR, IF ANY Frank S. Caruso	INVENTOR'S SIGNATURE Frank S. Caruso	DATE 8/04/2004
RESIDENCE Colts Necks, New Jersey	CITIZENSHIP United States of America	
POST OFFICE ADDRESS 2 Bowling Green, Colts Necks, NJ 07722-1300		
3. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY Peter Crooks	INVENTOR'S SIGNATURE	DATE
RESIDENCE Lexington, Kentucky	CITIZENSHIP United States of America	
POST OFFICE ADDRESS University of Kentucky, 501-B Pharmacy Building, Rose Street, Lexington, KY 40536-0082		
4. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY Kenneth J. Kellar	INVENTOR'S SIGNATURE	DATE
RESIDENCE Bethesda, Maryland	CITIZENSHIP United States of America	
POST OFFICE ADDRESS 7109 Burnham Place, Bethesda, MD 20817		
5. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY Yingxian Xiao	INVENTOR'S SIGNATURE	DATE
RESIDENCE Potomac, Maryland	CITIZENSHIP United States of America	
POST OFFICE ADDRESS 11713 Tiffon Drive, Potomac, MD 20854		
6. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
7. FULL NAME OF ADDITIONAL JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

2

PALM INTRANET

Day : Friday
Date: 12/23/2005
Time: 16:34:56

Application Number Information

Application Number: **10/501692** **Assignments** Examiner Number: **00000 /**
Filing or 371(c) Date: **00/00/0000** Group Art Unit: **0000** **IFW IMAGE**
Effective Date: **07/15/2004** Class/Subclass: **/.**
Application Received: **07/15/2004** Lost Case: **NO**
Patent Number: Interference Number:
Issue Date: **00/00/0000** Unmatched Petition: **YES**
Date of Abandonment: **00/00/0000** L&R Code: Secrecy Code:**1**
Attorney Docket Number: **END041182PCTUS** Third Level Review: **NO** Secrecy Order: **NO**
Status: **19 /APPLICATION UNDERGOING PREEXAM PROCESSING** Status Date: **07/23/2004**
Confirmation Number: **4419** Oral Hearing: **NO**
Title of Invention: **ANALGESICS AND METHODS OF USE**

Bar Code	PALM Location	Location Date	Charge to Loc	Charge to Name	Employee Name	Location

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data | Inventors |

Search Another: Application# [] Search **or Patent#** [] Search
PCT / [] / [] Search **or PG PUBS #** [] Search
Attorney Docket # [] Search
Bar Code # [] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page